Roundtable Roundup: Biomarker-Guided Therapy for HR+ Breast Cancer

Publication
Article
Peers & Perspectives in OncologyJune I 2024
Pages: 88

In separate, virtual live events, Sarah Sammons, MD, and Ruth O’Regan, MD, discussed molecular profiling and therapeutic options for a patient with advanced breast cancer after multiple lines of therapy.

CASE SUMMARY

  • A 52-year-old postmenopausal woman had a history of grade 2, node-negative invasive ductal carcinoma (IDC).
  • Estrogen receptor positive (ER+) and progesterone receptor positive (PR+); HER2 immunohistochemistry (IHC) 0; Ki-67 20% of the right breast; 21-gene recurrence score, 27
  • Initial therapy included chemotherapy, radiation therapy, and 5 years of adjuvant anastrozole.
  • Three years after completing anastrozole, metastatic progression was discovered, including symptomatic bone involvement (multiple vertebrae and bilateral iliac crests).
    • Bone marrow aspiration confirmed ER+/PR+, HER2 IHC 0, stage IV IDC.
    • ECOG performance status: 1
    • Mild anemia
  • The patient started letrozole and ribociclib (Kisqali) with denosumab (Xgeva), with good clinical response and marked improvement in her pain.
  • She required 1 dose reduction to 400 mg of ribociclib due to neutropenia.
  • Twenty months after starting therapy, routine staging scans showed new fluorodeoxyglucose-avid sclerotic and lytic bone lesions.
    • She noted mild increase in lower back pain.
    • Laboratory studies were normal.
  • Circulating tumor DNA (ctDNA) analysis confirmed an ESR1 mutation.
  • No evidence of PIK3CA/AKT1/PTEN mutations
sammons o'regan map
poll 1-breast cancer
poll 2- breast cancer
Related Videos
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Related Content